A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of Lebrikizumab in Adolescent Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication
Phase of Trial: Phase III
Latest Information Update: 05 Apr 2019
At a glance
- Drugs Lebrikizumab (Primary)
- Indications Asthma
- Focus Adverse reactions; Pharmacodynamics; Registrational; Therapeutic Use
- Acronyms ACOUSTICS
- Sponsors Chugai Pharmaceutical; Roche
- 31 Aug 2018 Biomarkers information updated
- 08 Mar 2017 Status changed from active, no longer recruiting to completed.
- 02 Nov 2016 Planned End Date changed from 1 Apr 2019 to 1 Dec 2016.